Presentation description

AML (Acute Myeloid Leukemia) is a cancer of the bone marrow diagnosed in about 20,000 Americans each year. The five-year survival rate is less than 33%, indicating the need for improved treatment options. While many AML patients respond to induction chemotherapy many will relapse due to persistence of quiescent AML cells. Quiescence allows AML cells to form resistance to chemotherapy, which makes the AML cells significantly harder to kill. Azeliragon is an inhibitor of RAGE that is currently in clinical development for different cancers. The goal of this project was to study the effect of azeliragon in combination with 2 standard of care drugs, daunorubicin and cytarabine, and determine whether the combinations provide synergistic effects against AML cells. These drugs were tested against 2 AML cell lines: HL-60, and OCI-AML-3.